ArtxTM platform and lead Program

Artus is developing new molecular entities (NME) inspired by beneficial naturally occurring host or microbial metabolites. Our oral small molecule therapies enhance barrier integrity of both epithelial and endothelial cells. 

These NMEs have the potential to be treatments for several gastrointestinal, neurological and metabolic disorders.

Unlike existing treatments, our developmental lead candidates, Artx-405, Artx-413 and Artx-425 enhance epithelial and endothelial barrier integrity , facilitating mucosal healing without compromising immunity.